Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-02-10 Major Shareholding Noti…
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2023-02-10 English
Regulatory Filings 2023
Regulatory Filings
2023-02-10 English
SCHEDULE 13G/A
Major Shareholding Notification
2023-02-09 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes details about the stock plans, incorporation by reference of prior filings, exhibits related to stock option agreements, and signatures of company officers. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing related to securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is over 10,000 characters, so it is not a mere announcement or notice but a full registration statement filing.
2023-02-07 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Registration Statement on Form S-3 filed with the SEC by Praxis Precision Medicines, Inc. It is a regulatory filing related to securities registration under the Securities Act of 1933. The document includes a base prospectus and a sales agreement prospectus supplement for securities offerings. It is not a financial report, earnings release, or management discussion, but rather a formal registration statement amendment for capital raising purposes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2023-02-07 English
10-K
Annual Report FY 2022
2023-02-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.